What is Lifesci Capital's Forecast for AQST Q3 Earnings?

Key Points

• Lifesci Capital has issued a Q3 2025 earnings estimate for Aquestive Therapeutics, forecasting a loss of ($0.15) per share, while maintaining a "Strong-Buy" rating on the stock.
• Aquestive Therapeutics reported Q2 earnings, beating estimates with a ($0.14) EPS compared to analyst expectations of ($0.18), although their revenue fell short at $10 million.
• The stock currently has a consensus rating of "Buy" with an average price target of $10.14, having experienced a 52-week range between $2.12 and $5.80.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) - Equities researchers at Lifesci Capital issued their Q3 2025 earnings per share (EPS) estimates for Aquestive Therapeutics in a research report issued to clients and investors on Wednesday, September 3rd. Lifesci Capital analyst F. Brisebois forecasts that the company will post earnings per share of ($0.15) for the quarter. Lifesci Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Aquestive Therapeutics' current full-year earnings is ($0.46) per share. Lifesci Capital also issued estimates for Aquestive Therapeutics' Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.65) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($0.86) EPS.

Several other equities research analysts have also weighed in on the company. Oppenheimer initiated coverage on Aquestive Therapeutics in a research note on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a report on Tuesday, June 17th. Finally, Zacks Research raised Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $10.14.

Aquestive Therapeutics Stock Performance

Shares of Aquestive Therapeutics stock traded up $0.36 during trading on Friday, reaching $5.42. The company's stock had a trading volume of 6,062,486 shares, compared to its average volume of 2,424,860. Aquestive Therapeutics has a one year low of $2.12 and a one year high of $5.80. The firm has a market cap of $540.48 million, a price-to-earnings ratio of -7.74 and a beta of 1.82. The business's fifty day moving average price is $3.98 and its 200-day moving average price is $3.25.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.04. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of Aquestive Therapeutics by 16.2% during the second quarter. Geode Capital Management LLC now owns 1,977,001 shares of the company's stock worth $6,545,000 after buying an additional 276,295 shares during the last quarter. Pale Fire Capital SE boosted its position in Aquestive Therapeutics by 25.5% during the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company's stock valued at $5,549,000 after acquiring an additional 340,767 shares during the last quarter. Janney Montgomery Scott LLC raised its holdings in shares of Aquestive Therapeutics by 7.6% during the first quarter. Janney Montgomery Scott LLC now owns 1,059,760 shares of the company's stock valued at $3,073,000 after purchasing an additional 75,275 shares during the period. Sio Capital Management LLC raised its holdings in shares of Aquestive Therapeutics by 141.9% during the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company's stock valued at $3,136,000 after purchasing an additional 555,860 shares during the period. Finally, Bank of America Corp DE raised its holdings in shares of Aquestive Therapeutics by 905.2% during the fourth quarter. Bank of America Corp DE now owns 690,284 shares of the company's stock valued at $2,457,000 after purchasing an additional 621,614 shares during the period. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.